bluebird bio (NASDAQ:BLUE) PT Lowered to $6.00 at Robert W. Baird

bluebird bio (NASDAQ:BLUE) had its price objective cut by Robert W. Baird from $7.00 to $6.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Separately, JPMorgan Chase & Co. lowered shares of bluebird bio from an overweight rating to a neutral rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, bluebird bio presently has an average rating of Hold and an average price target of $4.74.

bluebird bio Price Performance

Shares of BLUE opened at $0.71 on Thursday. The firm has a market capitalization of $77.53 million, a P/E ratio of -0.96 and a beta of 0.81. bluebird bio has a one year low of $0.68 and a one year high of $5.53. The business has a fifty day moving average of $1.02 and a 200 day moving average of $1.09.

Institutional Trading of bluebird bio

Several institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 1,013,144 shares during the period. Allegheny Financial Group LTD purchased a new position in shares of bluebird bio in the second quarter worth $25,000. Rhumbline Advisers lifted its stake in bluebird bio by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 59,219 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock valued at $675,000 after purchasing an additional 111,574 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of bluebird bio in the first quarter worth about $52,000. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.